KURE.L vs. SBIO.L

Last updated Jun 5, 2026

KURE.L (KraneShares MSCI All China Health Care Index UCITS ETF USD) and SBIO.L (Invesco Nasdaq Biotech UCITS ETF) are both Health & Biotech Equities funds - KURE.L tracks the MSCI World/Health Care NR USD while SBIO.L tracks the NASDAQ Biotechnology TR USD. Both are passively managed. Over the past year, KURE.L returned -10.89% vs 41.33% for SBIO.L. At a 0.30 correlation, their price movements are largely independent. KURE.L charges 0.65%/yr vs 0.40%/yr for SBIO.L.

Performance

KURE.L vs. SBIO.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, KURE.L achieves a -10.68% return, which is significantly lower than SBIO.L's 4.34% return.

KURE.L

• 1D: -2.87%
• 1M: -12.38%
• YTD: -10.68%
• 6M: -19.51%
• 1Y: -10.89%
• 3Y*: —
• 5Y*: —
• 10Y*: —

SBIO.L

• 1D: 3.10%
• 1M: 0.91%
• YTD: 4.34%
• 6M: 2.82%
• 1Y: 41.33%
• 3Y*: 12.99%
• 5Y*: 4.66%
• 10Y*: 7.49%

*Multi-year figures are annualized to reflect compound growth (CAGR)

KURE.L vs. SBIO.L - Yearly Performance Comparison

	2026 (YTD)	2025
KURE.L KraneShares MSCI All China Health Care Index UCITS ETF USD	-10.68%	11.52%
SBIO.L Invesco Nasdaq Biotech UCITS ETF	4.34%	37.44%

Correlation

The correlation between KURE.L and SBIO.L is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.29
Correlation (All Time) Calculated using the full available price history since Apr 29, 2025	0.30

KURE.L vs. SBIO.L - Sectors Allocation Comparison

Sectors	KURE.L	SBIO.L
Healthcare	98.3%	100.0%
Consumer Defensive	0.9%	-
Basic Materials	0.8%	-
Communication Services	0.0%	-
Consumer Cyclical	0.0%	-
Energy	0.0%	-
Financial Services	0.0%	-
Industrials	0.0%	-
Real Estate	0.0%	-
Technology	0.0%	-
Utilities	0.0%	-

Return for Risk

KURE.L vs. SBIO.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KURE.L

KURE.L Risk / Return Rank: 6
KURE.L Sharpe Ratio Rank: 6
KURE.L Sortino Ratio Rank: 6
KURE.L Omega Ratio Rank: 6
KURE.L Calmar Ratio Rank: 6
KURE.L Martin Ratio Rank: 6

SBIO.L

SBIO.L Risk / Return Rank: 72
SBIO.L Sharpe Ratio Rank: 64
SBIO.L Sortino Ratio Rank: 66
SBIO.L Omega Ratio Rank: 57
SBIO.L Calmar Ratio Rank: 89
SBIO.L Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KURE.L vs. SBIO.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) and Invesco Nasdaq Biotech UCITS ETF (SBIO.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KURE.L	SBIO.L	Difference
Sharpe ratio: Return per unit of total volatility	-0.33	2.09	-2.42
Sortino ratio: Return per unit of downside risk	-0.28	3.01	-3.29
Omega ratio: Gain probability vs. loss probability	0.97	1.35	-0.38
Calmar ratio: Return relative to maximum drawdown	-0.29	5.38	-5.67
Martin ratio: Return relative to average drawdown	-0.58	16.56	-17.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KURE.L vs. SBIO.L - Sharpe Ratio Comparison

The current KURE.L Sharpe Ratio is -0.33, which is lower than the SBIO.L Sharpe Ratio of 2.09. The chart below compares the historical Sharpe Ratios of KURE.L and SBIO.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	KURE.L	SBIO.L	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.33	2.09	-2.42
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.22	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.34	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.01	0.27	-0.28

Drawdowns

KURE.L vs. SBIO.L - Drawdown Comparison

The maximum KURE.L drawdown since its inception was -30.31%, smaller than the maximum SBIO.L drawdown of -39.44%. Use the drawdown chart below to compare losses from any high point for KURE.L and SBIO.L.

Drawdown Indicators

	KURE.L	SBIO.L	Difference
Max Drawdown Largest peak-to-trough decline	-30.31%	-39.44%	+9.13%
Max Drawdown (1Y) Largest decline over 1 year	-30.31%	-7.64%	-22.67%
Max Drawdown (3Y) Largest decline over 3 years	—	-26.88%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-38.33%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-38.33%	—
Current Drawdown Current decline from peak	-30.31%	-2.84%	-27.47%
Average Drawdown Average peak-to-trough decline	-11.49%	-16.83%	+5.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.98%	2.49%	+12.49%

Volatility

KURE.L vs. SBIO.L - Volatility Comparison

KraneShares MSCI All China Health Care Index UCITS ETF USD (KURE.L) has a higher volatility of 7.23% compared to Invesco Nasdaq Biotech UCITS ETF (SBIO.L) at 6.55%. This indicates that KURE.L's price experiences larger fluctuations and is considered to be riskier than SBIO.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KURE.L	SBIO.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.23%	6.55%	+0.68%
Volatility (6M) Calculated over the trailing 6-month period	18.31%	15.27%	+3.04%
Volatility (1Y) Calculated over the trailing 1-year period	26.92%	19.67%	+7.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	26.64%	21.21%	+5.43%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	26.64%	22.23%	+4.41%

KURE.L vs. SBIO.L - Expense Ratio Comparison

KURE.L has a 0.65% expense ratio, which is higher than SBIO.L's 0.40% expense ratio.

Dividends

KURE.L vs. SBIO.L - Dividend Comparison

Neither KURE.L nor SBIO.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both KURE.L and SBIO.L in my portfolio?

KURE.L and SBIO.L have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, KURE.L or SBIO.L?

On fees, SBIO.L is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, KURE.L or SBIO.L?

SBIO.L is cheaper with a 0.40% expense ratio, compared with 0.65% for KURE.L.

What is the main difference between KURE.L and SBIO.L?

KURE.L tracks MSCI World/Health Care NR USD, while SBIO.L tracks NASDAQ Biotechnology TR USD. They also come from different issuers: MLC Management and Invesco. Their fees differ too: 0.65% for KURE.L and 0.40% for SBIO.L.